Navigation Links
Celgosivir in Medical News

MIGENIX Reports Preliminary Celgosivir Viral Kinetics Study

VANCOUVER, and SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI, OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, has received preliminary four-week interim results from a Phase II viral kinetics study in hepatitis C virus ("HCV") treatment-naive patie...

New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report

...erferon II-58 Nautilus Biotech Commences Phase I Study for Belerofon(R) II-58 Migenix Announces Phase II Proof-of-Concept Study Results of celgosivir II-59 Pharmasset Begins Multiple Dose-Escalating Study of R7128 II-59 Transgene Commences Phase I Trial of TG4040 II-59 Debiopharm Release...
Celgosivir in Medical Technology

New Clinical Study Results Indicate Higher Early Virologic Response with Celgosivir Combination Therapy in HCV Non-Responders

Data to be Presented April 15th at EASL Conference in Barcelona, Spain VANCOUVER and SAN DIEGO, CA, April 11, 2007 /PRNewswire-FirstCall/ - MIGENIX Inc. , a clinical-stage developer of drugs for infectious diseases, has received new top-line results confirming the previously announced clinical res...

Migenix to Present Celgosivir Phase II Hepatitis C Results at Digestive Disease Week 2007

VANCOUVER and SAN DIEGO, May 18, 2007 /PRNewswire-FirstCall/ - MIGENIX Inc. , a clinical-stage developer of drugs for infectious diseases will make a presentation of results from a recent hepatitis C Phase II combination therapy study (see April 11, 2007 press release) in a non-responder patient p...

Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting

...bination With Peginterferon Alfa-2b in Treatment-Naive Patients With Chronic HCV; E.S. Maller, Monday, May 21, 2:15 p.m., Room 206 Phase II Study of celgosivir in combination with Peginterferon alfa-2b and ribavirin in chronic hepatitis C genotype 1 nonresponder patients; K.D. Kaita, Monday, May 21, 2:45 p.m....
Celgosivir in Biological Technology

MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study

VANCOUVER and SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI, OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, will add a 600mg celgosivir combination therapy arm to its currently enrolling Phase II viral kinetics study in hepatitis C virus ("HCV") ...

MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting

VANCOUVER and SAN DIEGO, Sept. 10 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases will present results of viral resistance studies with its anti-HCV agent celgosivir at the 14th International Symposium on Hepatitis C Vir...

MIGENIX Reports First Quarter Fiscal 2009 Financial Results

...cal study program (previously Cutanea was targeting the end of 2008). celgosivir (MX-3253; oral alpha-glucosidase I inhibitor; treatment of chronic hepatiti...e are continuing to seek strategic options for advancing the development of celgosivir and are currently in key partnering discussions. MX-2401 (IV lipopeptide;...

MIGENIX Corporate Update and Requisition of Special Meeting

...ayments and a single-digit royalty on net sales. celgosivir (oral alpha-glucosidase inhibitor for Hepatitis C ...rus infections): A Phase II study assessing 400 mg celgosivir for tolerability, pharmacokinetics and viral kinet...pment by the end of 2008; to have results from the celgosivir Phase II viral kinetics study in the next several ...

Migenix Takes Operational Actions To Extend Cash Past Upcoming Key Milestones

...nt payment(s), milestones and royalty terms celgosivir (hepatitis C virus): ----------------------------... - Program-related: The planned extension of the celgosivir viral kinetics study to include a 600 mg celgosivir combination arm (600 mg ...

MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results

...such a partnership(s) is uncertain at this time. celgosivir (MX-3253; oral alpha-glucosidase I inhibitor; trea...y is currently enrolling patients to assess 600 mg celgosivir for tolerability, pharmacokinetics and viral kinet... to the standard of care drugs alone and to 400 mg celgosivir plus the standard of care for up to 12 weeks of th...

MIGENIX releases CEO message #22

...n H2/08 - NDA submission in H1/09 - Rest of world partnership celgosivir (hepatitis C virus): - Phase II viral kinetics study results (includi... application (NDA) being submitted for OmigardTM in the first half of 2009; celgosivir Phase II viral kinetic results in the third quarter 2008; CLS001 entering i...

MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results

...) for omiganan 1% gel in the first half of 2009. celgosivir (MX-3253; oral alpha-glucosidase I inhibitor; trea...ncept and evidence of clinical benefit when adding celgosivir to the current standard-of-care HCV therapy (pegyl... (SVR). The safety profile for patients exposed to celgosivir for up to 48 weeks did not differ from those in th...

MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification

... Company to Report Interim celgosivir 4-Week Viral Kinetics Study Data on Monday December ...ort interim 4-week data from a Phase II viral kinetics combination study of celgosivir in patients with chronic HCV (genotype 1) infection on Monday December 3, 2...

MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

... Company Provides Revised Timing on Interim celgosivir Viral Kinetics Study ... prevention of catheter-related infections - celgosivir - a Phase II product candidate for treating chroni...rom a Phase II viral kinetics combination study of celgosivir in patients with chronic HCV (genotype 1) infectio...
Other Tags
(Date:4/17/2014)... the most popular vaccine brands for children may not ... overlooking some cost factors when choosing vaccines, driving the ... according to a new study by University of Illinois ... be driven by numerous factors," says Sheldon H. Jacobson, ... computer science and of mathematics at the U. of ...
(Date:4/17/2014)... Researchers at the University of California, San Diego School ... those who have suffered a recent major loss are ... older adults. , The study is published in this ... Psychiatry . , Because compassionate behaviors are associated with ... findings offer insights into ways to improve the outcomes ...
(Date:4/17/2014)... Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently invited ... of Nature Reviews Microbiology , one of ... a world-renowned infectious disease specialist, and chair of ... Tennessee Health Science Center, analyzed the epidemiology and ... 1968 pandemics, as well as more recent 2009 ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
(Date:4/17/2014)... one in five infants in the United States annually ... several months after birth. Research into probiotic use for ... April 1, 2014 issue of the British Medical ... "Probiotics and Infant Colic," concluding that the use of ... did not reduce crying or fussing in infants ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
(Date:4/17/2014)... IPCC meeting painted a stark warning on the possible ... a greenhouse effect 32 times that of carbon dioxide. ... humic substances act as fully regenerable electron acceptors which ... in wetlands instead of being released to the atmosphere. ... disrupted it may enter into a vicious cycle to ...
(Date:4/17/2014)... Branch at Galveston are the first to recommend ... cancer should begin colorectal cancer screening earlier than ... a high incidence of secondary colorectal cancers among ... recommendations that the younger women in this group ... their initial cervical cancer diagnosis instead of waiting ...
(Date:4/17/2014)... a special feature of The Proceedings ... ) published April 29, raises a number of startling ... most of us take for granted. At the end ... around the globe shifted from hunting animals and gathering ... It seems so straightforward and yet the more scientists ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2Radiation therapy for cervical cancer increases risk for colorectal cancer 2Genetic study tackles mystery of slow plant domestications 2Genetic study tackles mystery of slow plant domestications 3Genetic study tackles mystery of slow plant domestications 4
Other Contents